← All news

FROM THE NEWS FEED

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-08-06 • Psychedelic Invest

Article summary

Alignment with FDA on CMC and device plans for Phase 3Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estatePhase 2a results…

Continue to the original publication for the complete article.